Adaptive Biotechnologies ADPT Accretion (Amortization) of Discounts and Premiums, Investments
Accretion (Amortization) of Discounts and Premiums, Investments at other companies
Other financials
Where this comes from
Reported directly by Adaptive Biotechnologies in its filing.
Tagged under the XBRL concept us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments.
The official record: Adaptive Biotechnologies’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Adaptive Biotechnologies's accretion (amortization) of discounts and premiums, investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Adaptive Biotechnologies's accretion (amortization) of discounts and premiums, investments?
- Adaptive Biotechnologies (ADPT) reported accretion (amortization) of discounts and premiums, investments of $136K in Q1 2026.
- How has Adaptive Biotechnologies's accretion (amortization) of discounts and premiums, investments changed year-over-year?
- Adaptive Biotechnologies's accretion (amortization) of discounts and premiums, investments decreased by 85.8% year-over-year, from $958K to $136K.
- What is the long-term trend for Adaptive Biotechnologies's accretion (amortization) of discounts and premiums, investments?
- Over 3 years (2021 to 2025), Adaptive Biotechnologies's accretion (amortization) of discounts and premiums, investments has grown at a -29.7% compound annual growth rate (CAGR), from -$7.23M to $2.51M.
- What does accretion (amortization) of discounts and premiums, investments mean?
- This metric represents the non-cash adjustment to the carrying value of investment securities resulting from the amortization of premiums or the accretion of discounts. It reflects the adjustment of interest income to reflect the effective yield of the investment portfolio over time. This is a standard adjustment to reconcile net income to cash provided by operating activities.